Tris Pharma announced positive clinical data from its intranasal human abuse potential (HAP) study of cebranopadol. The study demonstrated...

Tris Pharma announced positive results from a Phase 1 intranasal human abuse potential (HAP) study of cebranopadol. The study...

Tevogen Bio (Nasdaq: TVGN), a clinical-stage immunotherapy biotech company, has secured up to $10 million in non-dilutive grant funding...

Silexion Therapeutics announced positive preclinical data for SIL-204, its RNAi therapeutic candidate targeting KRAS-driven cancers. The data validates systemic...

March Biosciences received FDA orphan drug designation for MB-105, its CD5-targeted CAR-T cell therapy for relapsed/refractory CD5-positive T-cell lymphoma....

SAB Bio announced positive topline data from a Phase 1 trial of SAB-142, a human anti-thymocyte immunoglobulin being developed...

Atai Life Sciences announced positive topline results from a Phase 2a study of BPL-003, a synthetic intranasal 5-MeO-DMT formulation,...

Data minimization is one of the fundamental principles of the General Data Protection Regulation (GDPR), aimed at ensuring that...

In this interview, we sit down with Mario Marcondes from Nektar Therapeutics to explore the advancements and potential of...

At the DPHARM conference, Eisai Inc. showcased their groundbreaking use of Bayesian methods to achieve accelerated approval for their...